REFERENCES
- Cybulska K, Kłos J. Antykoncepcja doustna a choroby układu krz˙enia u kobiet. Kardiol Pol 2000; 52(Suppl.3): 61–5
- Lech M, Swiatek E. Practices of prescribing oral contraceptives in Poland. Eur J Contracept Reprod Health Care 2001;6:27–33
- Wysocki S. A survey of American women regarding the use of oral contraceptives and weight gain (abstract). Int J Gynecol Obstet 2000; 70(Suppl 1):114
- Hatcher RA, Rinehart W, Blackburn R, et al. The Essentials of Contraceptive Technology. Baltimore: Population Information Council, The Johns Hopkins University, 2001:54–5
- Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control and side effects of low- and lower-dose oral contraceptives: a randomized trail of 20 mg, and 35 mg estrogen preparations. Contraception 2000;60:321–9
- Eck LH, Bennett AG, Egan BM, et al. Differences in macronutrient selections in users and nonusers of an oral contraceptive. Am J Clin Nutr 1997;65:419–24
- Kamin ski K, Wojdan R. Antykoncepcja z zastosowaniem nowej generacji niskodawkowych preparatow antykoncepcyjnych zawierajcych 20 lub 30 mg EE i 150 mg DSG –korzysci i ryzyko. Gin Prakt 2001;9(61):8–21
- PonJola C, Washenik K, Langley RGB, et al. Weight change and adverse event incidence with low-dose oral contraceptive: two randomized, placebo controlled trials. Contraception 2001;63:297–302
- Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995;51:283–8
- Aubeny E, Buhler M, Colau JC, et al. Oral contraception: patterns of non-compliance. The Coraliance study. Eur J Contracept Reprod Health Care 2002;7:155–61
- Goldzieher JW, Moses LE, Averkin E, et al. A placebo controlled double-blind crossover investigation of the side effects attributed to oral contracrptives. Fertil Steril 1971;22:609–23
- Redmond G, Godwin AJ, Olson W, Lippman J. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 2000;60:81–5
- Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Contraception 1998;58:345–9
- Pelkman CL, Heinbach RA, Rolls BJ. Reproductive hormones and eating behavior in young women. Appetite 2000;34:217–18
- Ball K, Brown W, Crawford D. Who does not gain weight? Prevalence and predictors of weight maintenance in young women. Int J Obes 2002;26:1570–8
- Ryan AS, Pratley RE, Elahi D. Resistive training increases fat-free mass and maintain RMR despite weight loss in postmenopausal women. Appl Physiol 1995;79:818–23
- Hassan DF, Petta CA, Aldrighi JM, et al. Weight variation in a cohort of women using cooper IUD for contraception. Contraception 2003;68:27–30
- Lech MM, Ostrowska L. Effects of low-dose OCs on weight in women with Central European nutritional habits and lifestyle. Contraception 2002;66:159–62
- Lloyd T, Hung Molin, Mathews AE, et al. Oral contraceptive use not associated with weight gain. Obstet Gynecol 2002;100:235–9
- Endrikat J, Gerlinger C, Cronin M, et al. Body weight change during use of a monophasic oral contraceptive containing 20 mg ethinylestradiol and 75 mg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake. Eur J Contracept Reprod Health Care 2001;6:199–204